The Food and Drug Administration will request Sarepta (SRPT) stop all shipments of its gene therapy Elevidys, Bhanvi Satija of Reuters reports, citing a source familiar with the matter. Shares of Sarepta are down 39%, or $8.56, to $13.41 following the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT: